The overall mortality (OM) and cancer-specific mortality (CSM) benefits of adjuvant radiotherapy (aRT) in treating prostate cancer (PCa) patients with adverse pathologic characteristics at radical prostatectomy (RP) are unclear.
To test the impact of aRT on survival in PCa patients treated with RP according to adverse pathologic characteristics (Gleason score [GS] 8-10; pT3b/4, lymph node invasion [LNI]) and age categories (<70 vs ≥70 yr).
A total of 7616 patients with pT3/4 pN0/1 PCa treated with RP between 1995 and 2009 within the Surveillance Epidemiology and End Results-Medicare linked database were included.
Cox regression analysis was used to test the relationship between aRT and CSM, as well as OM in the entire cohort. Stratification was performed according to tumor characteristics and age categories.
In patients with fewer than two adverse pathologic characteristics, aRT did not improve CSM or OM. Conversely, in patients with two or more adverse pathologic characteristics, the 10-yr CSM-free rate was 92% in patients treated with aRT versus 82% in patients treated without aRT (p<0.001). This survival improvement was confirmed in patients aged <70 yr (p=0.01) but not in those ≥70 yr (p=0.1). In multivariable analyses, aRT was an independent predictor of lower CSM risk (hazard ratio: 0.45; p=0.02) only among patients aged <70 yr with two or more adverse pathologic characteristics. Similar trends were observed when OM was examined as an end point.
Age and tumor characteristics should be considered in the selection of optimal aRT candidates after surgery. Only patients aged <70 yr with two or more adverse pathologic characteristics (GS 8-10, pT3b/4, LNI) appear to benefit from aRT.
The usefulness of adjuvant radiotherapy after surgery for prostate cancer greatly depends on tumor characteristics and patient age. Only patients with advanced local tumor characteristics aged <70 yr seem to benefit from this treatment modality.
This research output has an Altmetric Attention Score of 6. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 17 November 2015.
All research outputs
#9,565,167
of 34,410,315 outputs
Outputs from European Urology Focus
#917
of 1,672 outputs
Outputs of similar age
#84,225
of 301,981 outputs
Outputs of similar age from European Urology Focus
#12
of 21 outputs
Altmetric has tracked 34,410,315 research outputs across all sources so far. This one has received more attention than most of these and is in the 72nd percentile.
So far Altmetric has tracked 1,672 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 12.2. This one is in the 44th percentile – i.e., 44% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 301,981 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 72% of its contemporaries.
We're also able to compare this research output to 21 others from the same source and published within six weeks on either side of this one. This one is in the 42nd percentile – i.e., 42% of its contemporaries scored the same or lower than it.
